Reacciones al??rgicas por L-asparaginasa en ni?±os con leucemia linfoide aguda.

摘要

L-asparaginase is a medication used in different phases of all current treatment protocols for acute lymphoid leukemia. Multiple secondary manifestations to L- asparaginase are described, and allergic reactions are the most frequent. We studied 144 children with acute lymphoblastic leukemia treated at the Instituto de Hematolog?-a e Inmunolog?-a between 1998 and 2013. Thirty patients (21%) had allergic reactions, similar to what is described in literature; 76.6% of them had received a cumulative dose of less than 80 000 IU (average of 48 757); and the highest number of allergic reactions (86.7%) was reported between doses 9 and 18 received (mean of 11 doses). A greater global survival was observed in patients who received more doses (19 - 26 doses) (p=0.003). Event free survival was also higher in this group (p= 0.357).